T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model

High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)

(2019) Viola Franke et al.   INTERNATIONAL JOURNAL OF CANCER

One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).

(2019) Reinhard Dummer et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience

(2019) Raphael J. Louie et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Correlates of response and outcomes with talimogene laherperpvec

(2019) Alice Y. Zhou et al.   JOURNAL OF SURGICAL ONCOLOGY

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

(2019) Robert H. I. Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

(2019) Sabran J. Masoud et al.   ANNALS OF SURGICAL ONCOLOGY

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma

(2018) M T Tetzlaff et al.   ANNALS OF ONCOLOGY

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

(2018) Robert Hans Ingemar Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience

(2018) Matthew C. Perez et al.   ANNALS OF SURGICAL ONCOLOGY

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

A practical guide to the handling and administration of talimogene laherparepvec in Europe

(2017) Kevin Harrington et al.   OncoTargets and Therapy

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

(2016) Hasan Rehman et al.   Journal for ImmunoTherapy of Cancer

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

(2016) Howard L. Kaufman et al.   Journal for ImmunoTherapy of Cancer

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology